Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smooth AdCom Passage Expected For Novo's Semaglutide Despite Retinopathy Queries

Executive Summary

Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product available on the highly competitive US diabetes market, is expected to secure a market-leading spot, by revenue, before 2025.

Advertisement

Related Content

Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK
Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects
If Orexigen Disappears, Who's Left In The Obesity Market?
Novo's Semaglutide: Retinopathy Events Will Draw US FDA Panel's Focus
Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7
Novo Nordisk's Great Hope Semaglutide Shines In Ph II Obesity Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel